Loading…
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $62M | $-109M | $-102M | $-140M | -29.3% | 48.3% | - |
| 2024 | $42M | $-143M | $-130M | $-132M | -65.3% | 15.2% | - |
| 2023 | $37M | $-112M | $-102M | $-120M | -40.2% | 46.9% | - |
| 2022 | $25M | $-109M | $-108M | $-117M | -43.4% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 24.86 | 36.53 | 42.07 | 62.38 |
| Operating Expense | 135.93 | 150.70 | 187.66 | 173.67 |
| Operating Income | -111.07 | -114.17 | -145.59 | -111.29 |
| EBITDA | -109.46 | -111.76 | -143.10 | -109.01 |
| EBIT | -111.07 | -114.17 | -145.59 | -111.29 |
| Pretax Income | -108.12 | -101.61 | -130.09 | -101.59 |
| Tax Provision | 0.05 | 0.13 | 0.21 | 0 |
| Net Income | -108.18 | -101.74 | -130.30 | -101.59 |
| Net Income Common Stockholders | -108.18 | -101.74 | -130.30 | -101.59 |
| Total Expenses | 135.93 | 150.70 | 187.66 | 173.67 |
| Interest Income | 1.46 | 6.62 | 7.89 | 5.63 |
| Research And Development | 105.91 | 115.20 | 143.92 | 132.16 |
| Selling General And Administration | 30.02 | 35.50 | 43.75 | 41.51 |
| Normalized EBITDA | -109.46 | -111.76 | -143.10 | -109.01 |
| Normalized Income | -108.18 | -101.74 | -130.30 | -101.59 |
| Basic EPS | -1.23 | -1.08 | -1.19 | 0 |
| Diluted EPS | -1.23 | -1.08 | -1.19 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0.21 | 0.21 | 0.21 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -108.18 | -101.74 | -130.30 | -101.59 |
| Reconciled Depreciation | 1.61 | 2.42 | 2.50 | 2.28 |
| Net Interest Income | 1.46 | 6.62 | 7.89 | 5.63 |
| Net Income From Continuing And Discontinued Operation | -108.18 | -101.74 | -130.30 | -101.59 |
| Total Operating Income As Reported | -111.07 | -114.17 | -145.59 | -111.29 |
| Diluted Average Shares | 87.82 | 94.57 | 109.23 | 0 |
| Basic Average Shares | 87.82 | 94.57 | 109.23 | 0 |
| Diluted NI Availto Com Stockholders | -108.18 | -101.74 | -130.30 | -101.59 |
| Net Income Including Noncontrolling Interests | -108.18 | -101.74 | -130.30 | -101.59 |
| Net Income Continuous Operations | -108.18 | -101.74 | -130.30 | -101.59 |
| Other Income Expense | 1.49 | 5.94 | 7.61 | 4.07 |
| Other Non Operating Income Expenses | 1.49 | 5.94 | 7.61 | 4.07 |
| Net Non Operating Interest Income Expense | 1.46 | 6.62 | 7.89 | 5.63 |
| Interest Income Non Operating | 1.46 | 6.62 | 7.89 | 5.63 |
| General And Administrative Expense | 30.02 | 35.50 | 43.75 | 41.51 |
| Other Gand A | 30.02 | 35.50 | 43.75 | 41.51 |
| Operating Revenue | 24.86 | 36.53 | 42.07 | 62.38 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Tango Therapeutics, Inc.this co. | TNGX | $3.2B | - | 8.66 | -29.3% | -26.04 |
| Oruka Therapeutics, Inc. | ORKA | $3.4B | - | 7.07 | -22.5% | -24.94 |
| Liquidia Corporation | LQDA | $3.4B | - | 74.37 | -154.0% | -66.91 |
| Brookdale Senior Living Inc. | BKD | $3.4B | - | -74.95 | 605.6% | 18.66 |
| Edgewise Therapeutics, Inc. | EWTX | $3.3B |
| - |
| 6.20 |
| -32.1% |
| -14.47 |
| LivaNova PLC | LIVN | $3.2B | - | 2.68 | -20.2% | 11.72 |
| Beam Therapeutics Inc. | BEAM | $3.0B | - | 2.35 | -6.5% | -5.05 |
| Denali Therapeutics Inc. | DNLI | $3.0B | - | 2.87 | -50.6% | -3.93 |
| Alumis Inc. | ALMS | $2.9B | - | 7.95 | -80.8% | -6.02 |
| Peer Median | - | - | 4.53 | -27.3% | -5.54 | |